NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub ('HTH') Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute ('ARMI') and its BioFabUSA initiative.
NurExone's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market following the establishment of Exo-top Inc. ('Exo-TOP'), the Company's wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up.
HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants.
Dr. Lior Shaltiel, CEO of NurExone, commented: 'The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest healthcare market 2.'
NurExone's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs.
Omnibus Plan Approval
The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company's annual general and special meeting held on June 18, 2025 (the 'Meeting'), disinterested shareholders ratified and approved the amended and restated omnibus incentive plan (the 'Omnibus Plan'), a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca.
The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options ('Options'), restricted shares ('Restricted Shares') and restricted share units ('RSUs').
The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company's previous equity incentive plan approved by shareholders on June 4, 2024 (the 'Previous Plan'). The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company ('Common Shares') reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date.
The Omnibus Plan now includes (i) a 10% 'rolling' Option component that shall not exceed 10% of the Company's total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate.
Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company's securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company's securities issuable to insiders collectively shall not exceed 20% of the Company's total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company's other share compensation arrangements, shall not exceed 20% of the Company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider.
RSU Grants
In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. The RSUs and underlying Common Shares are subject to the Exchange Hold Period (as such term is defined under the policies of the TSX Venture Exchange ('TSXV')).
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@nurexone.com
Dr. Eva ReuterInvestor Relations – GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu
Allele Capital PartnersInvestor Relations – U.S.Phone: +1 978-857-5075Email: aeriksen@allelecapital.comThis press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the; the Company's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health.
These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company's acceptance into the prestigious HTH Accelerator Program will allow it to support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will give the Company the ability to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the Company's acceptance into the prestigious HTH Accelerator Program will not support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will not enhance its visibility within the U.S. regenerative medicine ecosystem and will not support its mission as discussed herein; each RSU will not be settled into one Common Share; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i Spinal cord injury, Glaucoma
1 https://www.epmscientific.com2 https://www.hbmhealthcare.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Wolfspeed nears bankruptcy deal with lenders including Apollo, Bloomberg News reports
(Reuters) -Wolfspeed will be taken over by creditors including Apollo Global Management under a proposal that would put the struggling chipmaker into bankruptcy, Bloomberg News reported on Wednesday, citing people familiar with the plan. The company will soon announce a deal for a so-called prepackaged bankruptcy, that would be long enough to slash billions in debt, the report said. After a restructuring support agreement is signed, Wolfspeed will ask creditors to vote on the plan and then file for Chapter 11 bankruptcy protection. Shares of Wolfspeed, which makes chips using silicon carbide — a more energy-efficient material than traditional silicon, rose about 3% to $1.29 on Wednesday. The stock had fallen about 81% so far this year. Wolfspeed and Apollo did not immediately respond to Reuters requests for comment. The chipmaker raised going-concern doubts earlier in May, as deepening economic uncertainty stemming from changing U.S. trade policies, combined with weakening demand, triggered a series of financial challenges for the company. As of March, the company had about $1.33 billion in unrestricted cash, cash equivalents and short-term investments, and about $6.5 billion of debt obligations, it said in a regulatory filing in May. In a prepackaged bankruptcy, companies and their creditors agree on a reorganization plan prior to the bankruptcy filing and creditors even vote on the plan. Shareholders could recover as much as 5% in the proposed scenario, the report said. In a typical bankruptcy, shareholders are usually wiped out because creditors must be paid first, and there often is not enough value left for equity holders. In 2023, Wolfspeed announced $1.25 billion in debt financing led by Apollo, with the option to increase the total to as much as $2 billion to support the company's U.S. expansion plans.
Yahoo
9 minutes ago
- Yahoo
On Juneteenth, Trump says the US has 'too many' holidays
Trump criticized the number of American holidays and claimed they cost billions in productivity. The post was made on Juneteenth, a federal holiday that Trump previously supported. Joe Biden later said making it a federal holiday was "one of the proudest moments of my presidency." Joe Biden has reiterated his support for Juneteenth as a federal holiday, after Donald Trump said America has "too many" of them. "Too many non-working holidays in America," Trump wrote on Truth Social late Thursday. "It is costing our Country $BILLIONS OF DOLLARS to keep all of these businesses closed." The president said that the frequency of holidays "must change" and that workers didn't want them, either. "The workers don't want it either!" he continued. "Soon we'll end up having a holiday for every once working day of the year. It must change if we are going to, MAKE AMERICA GREAT AGAIN!" Juneteenth, held on June 19 every year, commemorates the end of slavery in the United States and has long been celebrated by Black Americans. It became the 11th federal holiday in 2021 with a law signed by then-President Joe Biden. The bill passed with broad bipartisan support, receiving unanimous approval in the Senate and all but 14 votes in the House of Representatives. Biden later posted on X that he had celebrated the day in Texas and that making Juneteenth a federal holiday was "one of the proudest moments of my presidency." "It's a day of liberation. It's a day of remembrance. And it's a day of celebration. Today, it was an honor to be in Galveston where freedom rang out 160 years ago," he said. The White House press office didn't immediately respond to Business a request for comment from Business Insider regarding Trump's Truth Social post. Most federal offices, such as the US Postal Service, are closed during Juneteenth. Markets like the Nasdaq and New York Stock Exchange don't trade during the holiday, either. But whether private companies and state governments remain open varies. Most major banks are closed for the holiday, but not all companies provide paid time off. Earlier on Thursday, White House press secretary Karoline Leavitt said at a press briefing that the White House was open. When asked by a journalist about commemorating Juneteenth, she said she was "not tracking" Trump's signature on any proclamations for the holiday. "I know this is a federal holiday," she said. "I want to thank all of you for showing up to work. We are certainly here. We're working 24/7 right now." Trump himself supported making Juneteenth a federal holiday in the wake of widespread protests following the killing of George Floyd. "Make Juneteenth a National Holiday" was included among his "Promise to Black America over 4 years" policy proposals in his 2020 presidential campaign. During that campaign, Trump took credit for publicizing Juneteenth after moving one of his rallies from June 19 to June 20 in Tulsa, Oklahoma. "I did something good: I made Juneteenth very famous," Trump told The Wall Street Journal at the time. "It's actually an important event, an important time. But nobody had ever heard of it." In the same interview, Trump expressed surprise that his administration had commemorated Juneteenth every year. "Oh really? We put out a statement? The Trump White House put out a statement?" he said, according to the Journal. "OK, OK. Good." The White House did not publish a statement on its website commemorating Juneteenth this year. Read the original article on Business Insider
Yahoo
11 minutes ago
- Yahoo
Industrial Cleaning Solvents Market worth $1.55 billion by 2030 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., June 20, 2025 /PRNewswire/ -- The report "Industrial Cleaning Solvents Market by Application (General & Medical Device Cleaning, Metal Cleaners, Disinfectants), End-use Industry (Manufacturing and Commercial Offices, Healthcare, Retail & Food Service), and Region - Global Forecast to 2030", industrial cleaning solvents market size was estimated at USD 1.19 billion in 2024 and is projected to reach USD 1.55 billion by 2030, at a CAGR of 4.55% between 2025 and 2030. Browse in-depth TOC on "Industrial Cleaning Solvents Market"280 – Tables60 – Figures250 – Pages Download PDF Brochure: The industrial cleaning solvents market is undergoing a significant transformation, shifting from traditional formulations to more environmentally sustainable and low-VOC (volatile organic compound) options. Driven by the ongoing push for stricter environmental regulations and increasing corporate sustainability initiatives, manufacturers are transitioning from harsh chemical-based solvents to biodegradable, non-toxic solutions. This trend is particularly pronounced in industries such as hospitality, retail, and food service, where both workers and customers are frequently exposed to cleaning agents. Today's eco-conscious consumers, along with state and federal regulatory agencies, demand safer, greener products, fostering innovation in solvent formulations that safeguard indoor air quality, worker health, and the environment while still providing comparable cleaning power and operational efficiency performance. The disinfectants segment is projected to be the fastest-growing segment in terms of value in the global industrial cleaning solvents market during the forecast period. The disinfectants segment is projected to be the fastest-growing segment of the global industrial cleaning solvents market, in terms of value, during the forecast period. Since the pandemic, more attention has been given to sanitizing factories, warehouses, and processing units. Solvents of disinfectant grade are used to eliminate pathogens on surfaces, tools, and high-contact areas, making it less likely for people to spread illness. Regular disinfection has become part of the schedule in most industries that manage shared spaces. These disinfectants are preferred because they dry quickly and combat many types of germs, allowing work processes to continue without interruption. As a result of the pandemic, the demand for reliable and rapid-response industrial disinfectant solvents is increasing in various industries. Request Sample Pages: The healthcare industry accounted for the second-largest share of the industrial cleaning solvents market, in terms of value, in 2024. The healthcare industry accounted for the second-largest share of the global industrial cleaning solvents market, in terms of value, in 2024. It is also projected to be the fastest-growing industry during the forecast period. The rapid progress in healthcare across Asia, Africa, and South America is driving an increased demand for industrial cleaning solvents. Hospitals, diagnostic centers, and specialty clinics are being established to accommodate the growing number of patients. These facilities require efficient cleaning systems that adhere to international hygiene standards. As healthcare investments rise, the demand for professional-grade cleaning solvents also grows, supporting the expansion of the market. Europe was the third-largest region in the global industrial cleaning solvents market, in terms of value, in 2024. Europe was the third-largest region of the global industrial cleaning solvents market, in terms of value, in 2024. The robust automotive industry in Germany, France, and Italy drives greater use of industrial cleaning solvents in Europe. These solvents are utilized to maintain machines, clean auto components, degrease parts, and prepare surfaces for coating and painting. As electric vehicle production increases in Europe, the standards for component cleaning are being enhanced. The adoption of automated and robotic systems on the assembly lines boosts the use of high-performing and specialized solvents for precision cleaning in the region. Request Customization: The key players profiled in the report include Exxon Mobil Corporation (US), Shell plc (UK), BASF SE (Germany), Dow Inc. (US), LyondellBasell Industries N.V. (US), Eastman Chemical Company (US), Arkema (France), Celanese Corporation (US), Solvay S.A. (Belgium), Ashland Inc. (US), and Honeywell International Inc. (US). Get access to the latest updates on Industrial Cleaning Solvents Companies and Industrial Cleaning Solvents Market Size Browse Adjacent Market: Specialty Chemicals Market Research Reports & Consulting Related Reports: Solvents Market - Global Forecast to 2029 Industrial Cleaning Chemicals Market - Global Forecast to 2028 Industrial Rubber Market - Global Forecast to 2030 Plate & Frame Heat Exchanger Market - Global Forecast to 2030 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
